Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Evaxion Biotech is a clinical-stage Danish immunotherapy company developing AI-powered cancer vaccines and bacterial disease vaccines. The company's proprietary PIONEER and EDEN platforms use artificial intelligence to identify novel immunogenic targets for personalized and off-the-shelf cancer immunotherapies, as well as vaccines against bacterial infections. With zero revenue, negative operating cash flow, and a pre-commercial profile, the stock trades on clinical trial milestones, partnership announcements, and capital runway visibility.
Evaxion operates a discovery-to-clinic model using AI platforms (PIONEER for cancer neoantigens, EDEN for bacterial antigens) to identify immunogenic targets faster and cheaper than traditional methods. The business model relies on advancing multiple pipeline candidates through clinical trials, then either out-licensing to large pharma partners for milestone payments and royalties, or commercializing independently in niche indications. Value creation hinges on clinical data demonstrating immune response and efficacy, regulatory approvals, and strategic partnerships that validate the AI platform while providing non-dilutive funding. Current burn rate requires periodic capital raises through equity offerings or partnerships.
Clinical trial data readouts - Phase 1/2 safety, immunogenicity, and preliminary efficacy results for cancer vaccine candidates
Partnership announcements with large pharma companies providing validation and non-dilutive funding
Capital raises and cash runway visibility - equity offerings, warrant exercises, or debt financing announcements
FDA or EMA regulatory interactions - IND clearances, fast-track designations, or orphan drug status
AI platform validation - peer-reviewed publications or presentations demonstrating predictive accuracy of PIONEER/EDEN platforms
Clinical trial failure risk - cancer immunotherapy has high attrition rates with only 10-15% of Phase 1 oncology candidates reaching approval; single trial failure can eliminate years of investment
Capital markets dependency - pre-revenue model requires continuous access to equity financing; adverse market conditions or loss of investor confidence could force asset sales, unfavorable partnerships, or bankruptcy
AI platform validation risk - competitive advantage depends on PIONEER/EDEN platforms delivering superior target identification versus traditional methods; failure to demonstrate clinical superiority undermines entire thesis
Regulatory pathway uncertainty - personalized cancer vaccines face evolving FDA guidance on manufacturing, potency assays, and approval standards; changes could increase development costs or timelines
Large-cap competition from BioNTech, Moderna, Gritstone bio, and Neon Therapeutics in personalized cancer vaccines with significantly greater capital resources and manufacturing scale
Platform risk - multiple companies (Gritstone, Neon, BioNTech) also use AI/machine learning for neoantigen prediction; Evaxion must demonstrate differentiated clinical outcomes to justify premium partnership terms
Partnership dependency - without Big Pharma partnerships, company lacks resources for Phase 3 trials and commercialization; unfavorable deal terms or partnership failures could strand assets
Liquidity crisis risk - current ratio of 0.00 and negative operating cash flow indicate immediate capital needs; any financing delays create existential risk
Dilution risk - equity-dependent funding model with $0.0B market cap means future raises will be highly dilutive to existing shareholders at current valuations
Going concern risk - 100% gross margin with -440.6% operating margin reflects zero revenue against ongoing R&D spend; without partnership income or successful financing, company may not meet 12-month going concern threshold
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact pharma partnership activity, venture capital availability for follow-on financing, and investor risk appetite for pre-revenue biotech. The company's ability to raise capital at reasonable valuations is more sensitive to biotech sector sentiment than broad economic cycles.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (cancer vaccines likely 5-10+ years from commercialization). Higher rates also increase opportunity cost of holding cash-burning, pre-revenue assets versus fixed income alternatives, reducing speculative capital flows into early-stage biotech. Financing costs for any debt instruments increase, though Evaxion currently has zero debt. Rate environment affects NASDAQ Biotech Index sentiment, which drives sector-wide multiple compression or expansion.
minimal - No debt on balance sheet and pre-revenue stage means no credit-dependent business operations. However, tightening credit conditions reduce availability of venture debt as a non-dilutive financing option and can pressure biotech-focused funds that provide growth capital. Broader credit stress reduces pharma companies' willingness to commit upfront payments in licensing deals.
growth - highly speculative, binary-outcome investors seeking 10x+ returns from clinical success or partnership deals. Attracts biotech-specialized hedge funds, venture capital crossover funds, and retail momentum traders. Not suitable for value or income investors given pre-revenue status and high failure risk. Requires high risk tolerance and portfolio diversification to absorb potential total loss.
high - Clinical-stage biotech with minimal market cap exhibits extreme volatility around binary events (trial data, financing announcements, partnership news). Stock susceptible to 30-50%+ single-day moves on material updates. Illiquid trading and small float amplify price swings. Beta likely exceeds 2.0 versus broader market given sector-specific and idiosyncratic risks.